EVENT - Empowering Women Through Knowledge; Humanise Health & GeneType Launch "Know Your Risk”
April 08 2024 - 8:00AM
Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”,
“GTG”), a global leader in genomics-based tests in health, wellness
and serious disease, is pleased to announce an innovative
partnership between GTG, and Humanise Health launching a "Know Your
Risk" event featuring the company’s unique Risk Assessment
portfolio, to be held at The Langham, Pasadena, California on the
21st of May.
This unique gathering is dedicated to empowering
women by providing them with the knowledge and tools necessary for
proactive management of their health, with a special focus on the
advancements in genomics and personalised health strategies beyond
the well-known BRCA1/2 genes.
Empowerment, Understanding, and Action: The Core of
"Know Your Risk"
"Know Your Risk" is a movement towards
empowering every woman with the knowledge to take charge of her
health. Through engaging discussions led by renowned healthcare
professionals, attendees will explore the cutting-edge of genomics,
learn about the importance of risk assessment, and discover how
personalized health strategies can guide women in making informed
decisions about their health.
Event Highlights:
- Insightful Clinical
Learnings: Delve into the latest advancements in genomics
and their application in women's preventive health. With
Angelina Jolie’s Surgeon and world-renowned breast cancer
expert Dr Kristi Funk.
- Empowering
Advocacy Conversations: Global women’s health advocate
Krystal Barter will facilitate a discussion with thought-leaders
that aim to bring genetic testing and risk assessment to the
forefront of women’s health.
- Community Support:
Be part of the launch of a "Know Your Risk"
campaign, fostering a supportive community focused on empowering
women to make informed decisions about their health.
Krystal Barter, CEO of Humanise
Health, powerfully states: “I was fortunate to access
genetic testing and found out I carried the BRCA1 gene mutation.
Facing monumental decisions about my future health at a very young
age, the crucial thing was that I had the choice. This event is at
the heart of Humanise Health's mission to be a valued brand partner
in healthcare and: to illuminate and empower each person on their
unique health path. Co-hosting this event with my dear friend Dr.
Kristi Funk, alongside global advocates, the team at GeneType, and
our event partners, we're on the brink of transforming the
proactive approach to women's health."
Dr Erika Spaeth, director of clinical
and scientific affairs at geneType also added “we are
thrilled to be part of the conversation around progressing the
standards of women’s healthcare alongside distinguished clinicians,
passionate women’s health advocates and thought leaders. We are
entering an era of personalized medicine, and we want to facilitate
access to all women to improve preventive healthcare.
GeneType and Humanise Health are partnering
in a pioneering force in genomics. Together with Humanise Health, a
leading patient advocacy agency, we are at the forefront of
advocating for preventative health and personalized health
strategies. This partnership for the "Know Your Risk" event
underscores our collective dedication to empowering women with the
knowledge to proactively manage their health.
Authorised for release by the Board of
Directors.
Forward Looking Statements
This announcement may contain forward-looking
statements about the Company's expectations, beliefs or intentions
regarding, among other things, statements regarding the expected
use of proceeds. In addition, from time to time, the Company or its
representatives have made or may make forward-looking statements,
orally or in writing. Forward-looking statements can be identified
by the use of forward-looking words such as "believe," "expect,"
"intend," "plan," "may," "should" or "anticipate" or their
negatives or other variations of these words or other comparable
words or by the fact that these statements do not relate strictly
to historical or current matters. These forward-looking statements
may be included in, but are not limited to, various filings made by
the Company with the U.S. Securities and Exchange Commission, press
releases or oral statements made by or with the approval of one of
the Company's authorized executive officers. Forward-looking
statements relate to anticipated or expected events, activities,
trends or results as of the date they are made. As forward-looking
statements relate to matters that have not yet occurred, these
statements are inherently subject to risks and uncertainties that
could cause the Company's actual results to differ materially from
any future results expressed or implied by the forward-looking
statements. Many factors could cause the Company's actual
activities or results to differ materially from the activities and
results anticipated in such forward-looking statements as detailed
in the Company's filings with the Securities and Exchange
Commission and in its periodic filings with the ASX in Australia
and the risks and risk factors included therein. In addition, the
Company operates in an industry sector where securities values are
highly volatile and may be influenced by economic and other factors
beyond its control. The Company does not undertake any obligation
to publicly update these forward-looking statements, whether as a
result of new information, future events or otherwise, except as
required by law.
EnquiriesSimon
MorrissChief Executive OfficerGenetic
TechnologiesEmail Info@genetype.com
Genetic Technologies (NASDAQ:GENE)
Historical Stock Chart
From Oct 2024 to Nov 2024
Genetic Technologies (NASDAQ:GENE)
Historical Stock Chart
From Nov 2023 to Nov 2024